Domingo, P, de Benito, N. Alpha variant SARS-CoV-2 infection: How it all starts. EBioMedicine. 2021; 74DOI:10.1016/j.ebiom.2021.103703. PMID:34800902. IF:11.205(Q1/2D).

Camps-Vilaró, A, Teira, R, Subirana, I, Dégano, IR, Domingo, P, Curran, A, Montero-Alonso, M, Romero, A, Marrugat, J, Galindo, MJ. Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025; 160DOI:10.1016/j.ijid.2025.108061. PMID:40953693. IF:4.300(Q1/2D).

de Lazzari, E, Di Gregorio, S, Rojas, J, Curran, A, Domingo, P, Negredo, E, Tiraboschi, J, Gonzalez-Cordon, A, Torres, B, Sempere, A, Inciarte, A, Gatell, JM, Blanco, JL, Martinez, E. 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025; 80(8)DOI:10.1093/jac/dkaf192. PMID:40556520. IF:3.600(Q2/3D).

Giralt, M, Domingo, P, Quesada-López, T, Cereijo, R, Villarroya, F. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(14)DOI:10.3390/ijms26146546. PMID:40724797. IF:4.900(Q1/3D).

Ryan, P, Blanco, JL, Masia, M, Garcia-Fraile, L, Crusells, MJ, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Esteban, H, Gil, P, de Miguel, M, Alejos, B, Martínez, E. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025; 12(7)DOI:10.1016/S2352-3018(25)00105-5. PMID:40489982. IF:13.000(Q1/1D).

Rogg, L, Nuñez, SA, Mingrone, MVO, Domingo, P, Lopez, M, Hanan, N, Ghita, GL, Jeffrey, JL, Underwood, M, Castillo-Mancilla, JR, Halliday, F, Ezeadi, E, Gartland, M. Antiviral effect, safety, and tolerability of the third-generation integrase strand transfer inhibitor VH4524184 (VH-184): a proof-of-concept trial. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

Bailón, L, Moltó, J, Curran, A, Cadiñanos, J, de Quirós, JCLB, de los Santos, I, Ambrosioni, J, Imaz, A, Benet, S, Suanzes, P, Navarro, J, González-García, J, Busca, C, Pérez-Latorre, L, Berenguer, J, García-Fraile, LJ, Mejia-Abril, G, Miró, JM, Scévola, S, Moreno, S, Domingo, P, Tian, Y, Frankot, M, Lim, D, Cai, YH, Vendrame, E, Guo, S, Wallin, JJ, Geleziunas, R, Sengupta, D, Alarcón-Soto, Y, Leal, I, Aranguen, A, Garcia-Garcia, M, McGowan, I, Brander, C, Arribas, JR, Mothe, B. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-57284-w. PMID:40038256. IF:15.700(Q1/1D).

Suades, R, Greco, MF, Padró, T, de Santisteban, V, Domingo, P, Benincasa, G, Napoli, C, Greco, S, Madè, A, Ranucci, M, Devaux, Y, Martelli, F, Badimon, L. Blood CD45+/CD3+ lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; 55(2)DOI:10.1111/eci.14354. PMID:39548690. IF:3.600(Q1/2D).